<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Denis Libeert</style></author><author><style face="normal" font="default" size="100%">Dimitri Declercq</style></author><author><style face="normal" font="default" size="100%">Simeon Wanyama</style></author><author><style face="normal" font="default" size="100%">Muriel Thomas</style></author><author><style face="normal" font="default" size="100%">Sabine Van Daele</style></author><author><style face="normal" font="default" size="100%">Frans De Baets</style></author><author><style face="normal" font="default" size="100%">Stephanie Van Biervliet</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The effect of enteral tube feeding in cystic fibrosis: A registry based study.</style></title><secondary-title><style face="normal" font="default" size="100%">J Cyst Fibros</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Cystic Fibrosis</style></keyword><keyword><style  face="normal" font="default" size="100%">Gastrostomy</style></keyword><keyword><style  face="normal" font="default" size="100%">Malnutrition</style></keyword><keyword><style  face="normal" font="default" size="100%">Pulmonary function</style></keyword><keyword><style  face="normal" font="default" size="100%">Tube feeding</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2018</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2018 Mar</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">17</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;b&gt;BACKGROUND: &lt;/b&gt;Long-term effect of enteral tube feeding (ETF) in cystic fibrosis (CF) remains equivocal.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;METHODS: &lt;/b&gt;A Belgian CF registry based, retrospective, longitudinal study, evaluated the pre- and post- ETF (n = 113) clinical evolution and compared each patient with 2 age, gender, pancreatic status and genotype class-matched controls.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;RESULTS: &lt;/b&gt;At baseline ETF had a worse BMI z-score (p &amp;lt; 0.0001) and FEV1% (p &amp;lt; 0.0001) compared to controls. Patients eventually receiving ETF, had already a significant worse nutritional status and pulmonary function at first entry in the registry. Both parameters displayed a significant decline before ETF-introduction. ETF had more hospitalization and intravenous antibiotic (IVAB) treatment days (p &amp;lt; 0.0001). After ETF introduction hospitalizations and IVAB decreased significantly. After ETF-introduction BMI z-score recuperated towards the original curve before the decline, but remained below the controls. Starting ETF had no effect on rate of height gain in children. The pre-index FEV1 decline (-1.52%/year (p = 0.002)) stabilized to +0.39%/year afterwards. Controls displayed decline of -0.48%/year (p &amp;lt; 0.0001).&lt;/p&gt;

&lt;p&gt;&lt;b&gt;CONCLUSION: &lt;/b&gt;ETF introduction improved BMI z-score and stabilized FEV1, associated with less hospitalizations and IVAB treatments. Higher mortality and transplantation in the ETF cases, leading to drop-outs, made determination of the effect size difficult.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">2</style></issue></record></records></xml>